Imvaq Therapeutics Raises $15 Million in Series B Financing to Fund IND and Phase 1 Trials

NEXT STORY
The Truth About Digital Marketing During—And After—COVID
PREV STORY
Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis

 Top-line results are expected in the second quarter of 2017The randomized, double-blind, placebo-controlled Phase III study ...

author_avatar
NASDAQ Market News

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions

author_avatar
NASDAQ Market News

Worldwide Dried Blood Spot Collection Cards Industry to 2027 – Increasing Demand in Several Applications Presents Opportunities

author_avatar
NASDAQ Market News